Drugs for tuberculosis.
Author information unavailable
Abstract
Author information unavailable
Abstract
RECOMMENDATIONS: The standard treatment for latent tuberculosis is nine months of isoniazid taken daily, or twice weekly under direct observation by a healthcare worker. Taking isoniazid and rifapentine once weekly for 12 weeks under direct observation is an alternative for patients >12 years old. Initial therapy for patients with active or suspected tuberculosis should include isoniazid, rifampin,pyrazinamide and ethambutol until susceptibility is known. In patients with drug-susceptible pulmonary tuberculosis, the continuation phase of treatment should be a combination of isoniazid and either rifampin or rifapentine, taken for 4 or 7 months depending on risk factors. Confirmed multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis should be treated with directly observed therapy in collaboration with a clinician familiar with management of these conditions. Treatment must include at least 4 drugs to which the organism is susceptible; the duration of therapy should usually be 18-24 months. Directly observed therapy by a healthcare worker should be offered to all patients with active tuberculosis to minimize treatment failure, relapse and the emergence of drug resistance.
OpenAlex reports 2 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
RECOMMENDATIONS: The standard treatment for latent tuberculosis is nine months of isoniazid taken daily, or twice weekly under direct observation by a healthcare worker. Taking isoniazid and rifapentine once weekly for 12 weeks under direct observation is an alternative for patients >12 years old. Initial therapy for patients with active or suspected tuberculosis should include isoniazid, rifampin,pyrazinamide and ethambutol until susceptibility is known. In patients with drug-susceptible pulmonary tuberculosis, the continuation phase of treatment should be a combination of isoniazid and either rifampin or rifapentine, taken for 4 or 7 months depending on risk factors. Confirmed multidrug-resistant tuberculosis or extensively drug-resistant tuberculosis should be treated with directly observed therapy in collaboration with a clinician familiar with management of these conditions. Treatment must include at least 4 drugs to which the organism is susceptible; the duration of therapy should usually be 18-24 months. Directly observed therapy by a healthcare worker should be offered to all patients with active tuberculosis to minimize treatment failure, relapse and the emergence of drug resistance.
Key concepts: Rifapentine, Isoniazid, Pyrazinamide, Ethambutol, Tuberculosis, Medicine, Latent tuberculosis, Drug resistance